These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22723116)

  • 41. Medical management of peripheral arterial disease.
    Creager MA
    Cardiol Rev; 2001; 9(4):238-45. PubMed ID: 11405904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotherapy of intermittent claudication.
    Doggrell SA
    Expert Opin Pharmacother; 2001 Nov; 2(11):1725-36. PubMed ID: 11825312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
    Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
    Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of the cilostazol safety database.
    Pratt CM
    Am J Cardiol; 2001 Jun; 87(12A):28D-33D. PubMed ID: 11434897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Roset PN
    Br J Surg; 2013 Dec; 100(13):1838. PubMed ID: 24227374
    [No Abstract]   [Full Text] [Related]  

  • 46. Cilostazol.
    Sorkin EM; Markham A
    Drugs Aging; 1999 Jan; 14(1):63-71; discussion 72-3. PubMed ID: 10069409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2013 Dec; 100(13):1838-9. PubMed ID: 24227373
    [No Abstract]   [Full Text] [Related]  

  • 48. Joint torques and powers are reduced during ambulation for both limbs in patients with unilateral claudication.
    Koutakis P; Pipinos II; Myers SA; Stergiou N; Lynch TG; Johanning JM
    J Vasc Surg; 2010 Jan; 51(1):80-8. PubMed ID: 19837536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pentoxifylline for intermittent claudication.
    Salhiyyah K; Forster R; Senanayake E; Abdel-Hadi M; Booth A; Michaels JA
    Cochrane Database Syst Rev; 2015 Sep; 9(9):CD005262. PubMed ID: 26417854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphodiesterases as targets for intermittent claudication.
    Liu Y; Shakur Y; Kambayashi J
    Handb Exp Pharmacol; 2011; (204):211-36. PubMed ID: 21695642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
    Donnelly R
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S20-5. PubMed ID: 12180354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cilostazol approved for use in intermittent claudication.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):404. PubMed ID: 10096695
    [No Abstract]   [Full Text] [Related]  

  • 53. Management of peripheral arterial disease in the elderly: focus on cilostazol.
    Falconer TM; Eikelboom JW; Hankey GJ; Norman PE
    Clin Interv Aging; 2008; 3(1):17-23. PubMed ID: 18488875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pentoxifylline for intermittent claudication.
    Salhiyyah K; Senanayake E; Abdel-Hadi M; Booth A; Michaels JA
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005262. PubMed ID: 22258961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of relationship between gait parameters and physical function in peripheral arterial disease.
    Scherer SA; Hiatt WR; Regensteiner JG
    J Vasc Surg; 2006 Oct; 44(4):782-8. PubMed ID: 17012002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
    Hood SC; Moher D; Barber GG
    CMAJ; 1996 Oct; 155(8):1053-9. PubMed ID: 8873633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cilostazol: a replacement for pentoxifylline?
    Shukla V
    Issues Emerg Health Technol; 1999 Jul; (7):1-4. PubMed ID: 11811214
    [No Abstract]   [Full Text] [Related]  

  • 59. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Randomized study of tolerability, safety and efficacy of Pletax in intermittent claudication].
    Kazantsev AN; Goriunov SV; Ershova OB; Erofeeva SB; Gurgenian EV
    Angiol Sosud Khir; 2021; 27(1):7-16. PubMed ID: 33825723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.